Edition: United Kingdom  
One News Page
“Probably the fastest-access news portal in the world”
Actelion News  |<  Page 1  >> 
Share on
Share on
Post on 
Share by

Johnson & Johnson reports dip in quarterly profit

(Reuters) - Johnson & Johnson , which completed its $30 billion acquisition of Swiss biotech Actelion last month, reported a 4.3 percent fall in quarterly profit, as costs rose.

Actelion spin-off Idorsia up 30% on market debut

Pharma group valued at SFr1.5bn despite no significant revenues expected for 3 years

Videos for actelion

News video: J&J CEO Gorsky on M&A, Health Care, Tax Reform

J&J CEO Gorsky on M&A, Health Care, Tax Reform 15:01

Jun.26 -- Alex Gorsky, chairman and chief executive officer at Johnson & Johnson, discusses the company’s purchase of Actelion, the state of health care in the United States, and what tax reform..
Source: Bloomberg Politics -

News video: January a Banner Month for Global M&A Despite Uncertainty

January a Banner Month for Global M&A Despite Uncertainty 03:20

Feb.06 -- Bloomberg’s Jeff McCracken discusses global deal activity in January, President Trump’s tax proposals and mergers and acquisitions in an unpredictable market. He speaks on “Bloomberg..
Source: Bloomberg Global Business -

News video: Weekly Wrap: Dow Hits 20,000, J&J Looks for Growth

Weekly Wrap: Dow Hits 20,000, J&J Looks for Growth 02:39

We look at what the Dow's new milestone means for investors. Plus, Johnson & Johnson looks to boost its prospects, and United Technologies looks cheap.
Source: Morningstar.com -

News video: J&J Acquires Actelion for $$30 Billion

J&J Acquires Actelion for $$30 Billion 02:15

Jan.26 -- Bloomberg’s Jeffrey McCracken reports on Johnson & Johnson’s $30 billion acquisition of Actelion. He speaks on “Bloomberg Markets.”
Source: Bloomberg Global Business -

News video: Those Who Benefit From Johnson & Johnson Takeovers

Those Who Benefit From Johnson & Johnson Takeovers 00:31

Johnson & Johnson is enacting at $30 billion takeover of Europe’s biggest biotech company, Actelion. Johnson & Johnson is known for buying Swiss medical companies, and those who own stock in the..
Source: Wochit Headline News -


EU approves Johnson & Johnson's $30bn purchase of Actelion

eu approves johnson & johnson's $30bn purchase of actelion
The European Commission today approved the planned sale of Swiss pharmaceuticals firm Actelion to Johnson & Johnson (J&J), subject to conditions. EU regulators qualified the sale of Europe's biggest..
City A.M.

J&J garners EU approval for $30bn Actelion deal


EU approves J&J purchase of Actelion subject to conditions

BRUSSELS (Reuters) - EU antitrust regulators approved on Friday Johnson & Johnson's planned purchase of Actelion Pharmaceutical subject to conditions intended to ensure clinical development of insomnia..

Actelion antibiotic misses mark on one study, hits it on another

ZURICH (Reuters) - Swiss biotechnology company Actelion on Thursday presented mixed trial results for its antibiotic hopeful cadazolid, saying it met the main goal of one late-stage study but failed to..

J&J's quarterly sales rise 1.6 percent

(Reuters) - Johnson & Johnson, which is in the process of completing its $30 billion acquisition of Swiss biotech Actelion, reported on Tuesday a 1.6 percent rise in first-quarter sales.

EMA gives green light to Actelion's Uptravi after safety review

ZURICH (Reuters) - The European Medicines Agency on Friday gave its green light for doctors to continue using Actelion's Uptravi, saying a review after five patient deaths in France did not suggest an..

J&J declares Actelion tender offer a success, sees closing in second quarter

ZURICH (Reuters) - Johnson & Johnson declared its $30 billion tender offer for Swiss biotechnology company Actelion successful on Friday, reporting it controlled 77.2 percent of the voting rights after..

It's official: Deal volumes hit highest level since the financial crisis

it's official: deal volumes hit highest level since the financial crisis
Global M&A activity so far this year is at its highest level since the financial crisis, expert analysis has revealed. Some $705bn of deals have been announced since the start of 2017, the first..
City A.M.

Actelion, being bought by J&J, says full year profit rose 26 percent

ZURICH (Reuters) - Swiss drugmaker Actelion said on Tuesday that its full year 2016 net income rose 26 percent on accelerating sales of its newer medicines to treat deadly pulmonary arterial..

MY INVESTMENTS: Samantha Gleave on Actelion and Opap

my investments: samantha gleave on actelion and opap
Actelion Pharmaceuticals had a very attractive pipeline of new drugs in development. But OPAP, a Greek lottery and sports betting operator, was hit hard by the political crisis in the country.

EMA panel recommends that use of Actelion's Uptravi may continue

ZURICH (Reuters) - A European Medicines Agency drug safety panel recommended on Friday that Actelion's Uptravi drug may continue to be used in line with current prescription information amid a probe..

BRIEF-J&J says upon termination of transaction agreement, under some circumstances, Actelion may be obligated to pay co a fee

* J&J - upon termination of transaction agreement, under some circumstances, Actelion may be obligated to pay co a fee - sec filing Source text - http://bit.ly/2jWFeAh Further company coverage:

Actelion, Syngenta takeovers set to shake up Swiss SMI index

ZURICH (Reuters) - The looming foreign takeovers of biotech group Actelion and agrichemicals firm Syngenta look set to trigger the biggest shake-up in the Swiss blue-chip SMI index in years just as..

J&J digs deep to claim $30bn Actelion prize

Biggest deal in group’s 130-year history is unusual in timing and concessions made

J&J boss’s long quest ends with Actelion deal

Questions asked about price paid for Swiss group and spin-off of promising new drugs

You Might Like

 |<  Page 1  >> 
Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2017 One News Page Ltd. All Rights Reserved.  |  About us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Privacy Policy  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  Help  |  Contact us  |  DMCA / Content Removal
How are we doing? Send us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter   FIND us on Google+